Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | YAP1 | P46937 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27902140 | 0.92 | GLS (0.49) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL12425116 | 0.92 | GLS (0.49) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL6637782 | 0.87 | KDM4E (0.49) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL2300227 | 0.85 | NR1H2 (0.51) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL21551314 | 0.84 | GLS (0.54) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL25327252 | 0.83 | GLS (0.41) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL18508122 | 0.83 | GLS (0.58) | GLSEPHX1HPGDALDH1A1 | |
| SCHEMBL3220460 | 0.83 | HPGD (0.51) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL5889076 | 0.83 | YAP1 (0.56) | GLSKDM4EPKMEPHX1HPGD | |
| SCHEMBL5573225 | 0.83 | KDM4E (0.63) | GLSKDM4EPKMEPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610260-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Shenshi Wise Technology Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-117946111-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-9845323-B2 | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-12-19 | — | — | US | disclosed |
| US-9657022-B2 | 7-OXO-1,6-diazabicyclo[3.2.1]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-05-23 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2017-02-16 | — | — | US | disclosed |
| US-9522901-B2 | Compositions and methods including cell death inducers and procaspase activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522901-B2 | Compositions and methods including cell death inducers and procaspase activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160297816-A1 | 2-(1,3,4-OXADIAZOL-2-YL)-7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-10-13 | — | — | US | disclosed |
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2008134474-A2 | COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-1996005185-A1 | NOVEL ALKYLAMINO DERIVATIVES AS SIGMA 2 SELECTIVE LIGANDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | CASP3, CASP6, CASP5 | GLS 160/4885KDM4E 1245/4885PKM 1793/4885 |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | CASP3, CASP6, CASP5 | GLS 160/4885KDM4E 1245/4885PKM 1793/4885 |
| US-20160297816-A1 | 2-(1,3,4-OXADIAZOL-2-YL)-7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ODC1, OXA1L, CASP7 | GLS 2130/4885KDM4E 4131/4885PKM 4043/4885 |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | GLS 135/4885KDM4E 529/4885PKM 1024/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | GLS 101/4885KDM4E 1254/4885PKM 1197/4885 |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, CASP6, CASP5 | GLS 135/4885KDM4E 529/4885PKM 1024/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | GLS 101/4885KDM4E 1254/4885PKM 1197/4885 |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CASP7, ODC1, CASP1 | GLS 2179/4885KDM4E 4179/4885PKM 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.